Liposarcoma

Oncology
8
Pipeline Programs
7
Companies
22
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
3
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

Novartis
VOTRIENTApproved
pazopanib hydrochloride
Novartis
oral2009

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
1
VOTRIENT(pazopanib)Phase 2Small Molecule5 trials
Active Trials
NCT05180695Active Not Recruiting47Est. Feb 2027
NCT02203760Active Not Recruiting58Est. Dec 2024
NCT02383251Completed118Est. Dec 2020
+2 more trials
Alliance Pharmaceuticals
1 program
1
efatutazonePhase 2
DS
Daiichi SankyoChina - Shanghai
1 program
1
efatutazonePhase 21 trial
Active Trials
NCT02249949Completed15Est. May 2023
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
1
Eribulin MesylatePhase 11 trial
Active Trials
NCT03361436Active Not Recruiting15Est. Apr 2033
E
EisaiChina - Liaoning
1 program
1
Eribulin MesylatePhase 1
Karyopharm Therapeutics
1 program
1
SelinexorPhase 1
Takeda
TakedaTOKYO, Japan
1 program
1
SelinexorPhase 11 trial
Active Trials
NCT03880123Withdrawn0Est. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Novartispazopanib
Novartispazopanib
Novartispazopanib
Novartispazopanib
Novartispazopanib
Novartispazopanib
Daiichi Sankyoefatutazone
Novartispazopanib
Novartispazopanib
Novartispazopanib
Novartispazopanib
Novartispazopanib
Novartispazopanib
Novartispazopanib
TakedaSelinexor

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 2,030 patients across 22 trials

NCT01521715Novartispazopanib

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

Start: Jan 2012Est. completion: Jul 201744 patients
Phase 4Completed
NCT01064310Novartispazopanib

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

Start: May 2010Est. completion: Nov 2015169 patients
Phase 3Completed
NCT02203760Novartispazopanib

Pazopanib Vs. Pazopanib Plus Gemcitabine

Start: Oct 2019Est. completion: Dec 202458 patients
Phase 2Active Not Recruiting
NCT02383251Novartispazopanib

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Start: Jun 2015Est. completion: Dec 2020118 patients
Phase 2Completed
NCT02193152Novartispazopanib

Pazopanib in Molecularly Selected Patients With Advanced NSCLC

Start: Apr 2015Est. completion: Dec 201916 patients
Phase 2Terminated
NCT02300545Novartispazopanib

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Start: Apr 2015Est. completion: Jul 202056 patients
Phase 2Completed
NCT02249949Daiichi Sankyoefatutazone

Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

Start: Feb 2015Est. completion: May 202315 patients
Phase 2Completed
NCT01392183Novartispazopanib

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Start: Oct 2012Est. completion: Sep 201969 patients
Phase 2Completed
NCT01593748Novartispazopanib

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Start: Sep 2012Est. completion: Apr 201990 patients
Phase 2Completed
NCT01610206Novartispazopanib

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Start: Sep 2012Est. completion: Dec 2020148 patients
Phase 2Completed
NCT01506596Novartispazopanib

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Start: Mar 2012Est. completion: Mar 201642 patients
Phase 2Completed
NCT01566747Novartispazopanib

Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5

Start: Mar 2011Est. completion: Jul 202043 patients
Phase 2Completed
NCT05180695Novartispazopanib

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Start: Apr 2022Est. completion: Feb 202747 patients
Phase 1/2Active Not Recruiting
NCT02055690Novartispazopanib

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

Start: Sep 2014Est. completion: Nov 201721 patients
Phase 1/2Terminated
NCT03880123TakedaSelinexor

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Start: Nov 2020Est. completion: Nov 20200
Phase 1Withdrawn
NCT03361436Knight TherapeuticsEribulin Mesylate

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Start: Mar 2018Est. completion: Apr 203315 patients
Phase 1Active Not Recruiting
NCT01716416Novartispazopanib

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

Start: May 2013Est. completion: Aug 201732 patients
Phase 1Completed
NCT01642017Novartispazopanib

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Start: Nov 2012Est. completion: Mar 201818 patients
Phase 1Terminated
NCT01543763Novartispazopanib

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Start: Jun 2012Est. completion: Dec 202490 patients
Phase 1Completed
NCT01438554Novartispazopanib

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Start: Oct 2011Est. completion: Aug 201889 patients
Phase 1Completed
NCT00387205Novartispazopanib

Study To Assess Long Term Safety Of Pazopanib

Start: Jun 2006Est. completion: Mar 2018188 patients
Phase 1Completed
NCT01649778Novartispazopanib

Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma

Start: Jul 2012Est. completion: Jul 2017662 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
7m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
7m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
18m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
21m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
21m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)